Rezetamig

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A human bispecific antibody, with potential antineoplastic activity. Rezetamig contains two binding sites, one for the tumor-associated antigen (TAA) CD22, and one for the T-cell surface antigen CD3. Upon administration, rezetamig binds to both CD3 on T-cells and CD22-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD22-expressing tumor B-cells. CD22 is exclusively expressed on B-cells and is often overexpressed in B-lymphocytic malignancies. It negatively regulates the B-cell receptor.

**Synonyms:** - Anti-CD22/CD3 Bispecific Antibody JNJ-75348780 - CD22 x CD3 Bispecific Antibody JNJ-75348780 - JNJ 75348780 - JNJ-75348780 - JNJ75348780 - REZETAMIG